Literature DB >> 20801063

Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury.

Eran Gabay1, Gilly Wolf, Yehuda Shavit, Raz Yirmiya, Michael Tal.   

Abstract

Neuropathic pain is a chronic pain state resulting from peripheral nerve injury, characterized by hyperalgesia and allodynia. We have reported that mice with genetic impairment of IL-1 signaling display attenuated neuropathic pain behavior and ectopic neuronal activity. In order to substantiate the role of IL-1 in neuropathic pain, WT mice were implanted subcutaneously with osmotic micropumps containing either IL-1ra or vehicle. Two days following the implantation, two models of neuropathic pain were used; partial nerve injury (spinal nerve transection, SNT), or complete nerve cut (spinal neuroma model). Mechanosensitivity was assessed seven consecutive days following SNT, and on day 7 recordings of spontaneous ectopic activity were performed. In the spinal nerve neuroma model, autotomy scores were recorded up to 35 days. Vehicle-treated mice developed significant allodynia and autotomy, and clear ectopic activity (4.1±1.1% of the axons); whereas IL-1ra-treated mice did not display allodynic response, displayed delayed onset of autotomy and markedly reduced severity of autotomy scores, and displayed reduced spontaneous activity (0.8±0.4% of the axons). To test whether IL-1 is involved in maintenance of mechanical allodynia, a separate group of WT mice was treated with a single injection of either saline or IL-1ra four days following SNT, after the allodynic response was already manifested. Whereas saline-treated mice displayed robust allodynia, acute IL-1ra treatment induced long-lasting attenuation of the allodynic response. The results support our hypothesis that IL-1 signaling plays an important role in neuropathic pain and in the ectopic neuronal activity that underling its development.
Copyright © 2010 European Federation of International Association for the Study of Pain Chapters. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20801063     DOI: 10.1016/j.ejpain.2010.07.012

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  30 in total

1.  Design of a superior cytokine antagonist for topical ophthalmic use.

Authors:  Jinzhao Hou; Sharon A Townson; Joseph T Kovalchin; Allyson Masci; Olga Kiner; Yanqun Shu; Bracken M King; Emily Schirmer; Kathryn Golden; Christoph Thomas; K Christopher Garcia; Gregory Zarbis-Papastoitsis; Eric S Furfine; Thomas M Barnes
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

Review 2.  Inflammasomes in carcinogenesis and anticancer immune responses.

Authors:  Laurence Zitvogel; Oliver Kepp; Lorenzo Galluzzi; Guido Kroemer
Journal:  Nat Immunol       Date:  2012-03-18       Impact factor: 25.606

3.  Upregulation of CXCR4 through promoter demethylation contributes to inflammatory hyperalgesia in rats.

Authors:  Feng Li; Zhou-Ya Xue; Yuan Yuan; Sai-Sai Huang; Yi-Hui Fan; Xiang Zhu; Lei Wei
Journal:  CNS Neurosci Ther       Date:  2018-03-25       Impact factor: 5.243

Review 4.  Chronic neuropathic pain-like behavior and brain-borne IL-1β.

Authors:  Adriana del Rey; A Vania Apkarian; Marco Martina; Hugo O Besedovsky
Journal:  Ann N Y Acad Sci       Date:  2012-07       Impact factor: 5.691

5.  Neuraxial TNF and IFN-beta co-modulate persistent allodynia in arthritic mice.

Authors:  Sarah A Woller; Cody Ocheltree; Stephanie Y Wong; Anthony Bui; Yuya Fujita; Gilson Gonçalves Dos Santos; Tony L Yaksh; Maripat Corr
Journal:  Brain Behav Immun       Date:  2018-11-19       Impact factor: 7.217

6.  Increased excitability of medium-sized dorsal root ganglion neurons by prolonged interleukin-1β exposure is K(+) channel dependent and reversible.

Authors:  Patrick L Stemkowski; Myung-Chul Noh; Yishen Chen; Peter A Smith
Journal:  J Physiol       Date:  2015-07-26       Impact factor: 5.182

Review 7.  Schwann cell interactions with axons and microvessels in diabetic neuropathy.

Authors:  Nádia P Gonçalves; Christian B Vægter; Henning Andersen; Leif Østergaard; Nigel A Calcutt; Troels S Jensen
Journal:  Nat Rev Neurol       Date:  2017-01-30       Impact factor: 42.937

8.  A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease.

Authors:  Kerry S Russell; Denise P Yates; Christopher M Kramer; Andrea Feller; Ping Mahling; Laurence Colin; Timothy Clough; Tianke Wang; Lucy LaPerna; Alpa Patel; Holger Lawall; Mustafa M Shennak; James Fulmer; Sigrid Nikol; William B Smith; Oliver J Müller; Elizabeth V Ratchford; Craig T Basson
Journal:  Vasc Med       Date:  2019-07-05       Impact factor: 3.239

9.  Neuroglial activation in the auditory cortex and medial geniculate body of salicylate-induced tinnitus rats.

Authors:  Chenchen Xia; Manli Yin; Cong Wu; Yonghua Ji; You Zhou
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

10.  Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.

Authors:  Francisco Amparo; Mohammad H Dastjerdi; Andre Okanobo; Giulio Ferrari; Leila Smaga; Pedram Hamrah; Ula Jurkunas; Debra A Schaumberg; Reza Dana
Journal:  JAMA Ophthalmol       Date:  2013-06       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.